EGFR and jejunal neoplasm: The most notable differences between segments were seen in ERBB signalling which was less frequently mutated in ileal tumors (9/16, 56.3%) compared duodenal and jejunal tumors (20/24, 83.3% and 38/44, 86.4%, respectively) (P = 0.0463) and in ERK/MAPK signalling, most frequently affected in jejunal tumors (40/44, 90.9%) compared to duodenal and ileal tumors (18/24, 75.0% and 9/16, 56.3%, respectively) (P = 9.06x10-3).